Drug Profile
Research programme: synthetic cannabinoid therapeutics - Claritas Pharmaceuticals
Alternative Names: K 439; K-1012; K-1022; K-1032; K-1052; K-436; K-671; KAL 436; KAL 439; KAL 671; Synthetic fatty acid amide - Claritas PharmaceuticalsLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Developer Claritas Pharmaceuticals; Kalytera Therapeutics; Tel Aviv University
- Class Anti-inflammatories; Cannabinoids; Fatty acids; Osteoporosis therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Bone development modulators; Bone resorption factor inhibitors; Cannabinoid receptor CB1 antagonists; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acne vulgaris; Respiratory distress syndrome; Sepsis; Ulcerative colitis
- Discontinued Fracture; Osteogenesis imperfecta; Osteoporosis
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Acne-vulgaris in USA
- 28 May 2021 No recent reports of development identified for research development in Respiratory-distress-syndrome in USA
- 28 May 2021 No recent reports of development identified for research development in Sepsis in USA